
    
      Inclusion criteria were as follows: women of good physical and mental health, under 37 years
      old, with regular menstrual cycles of 25-35 days, normal basal FSH and luteinizing hormone
      (LH) levels, body mass index (BMI) less than 30 kg/m2, presence of both ovaries and intact
      uterus, absence of polycystic ovaries, endometriosis, or gynaecological / medical disorders
      and a negative result in a screening for sexually transmitted diseases.

      No patient had received any hormone therapy for at least 60 days preceding the study.
      Eligible patients who agreed to participate were randomized in two treatment groups. Patients
      were allocated to a GnRH analogue treatment group according to a computer-generated
      randomization table.
    
  